Price:
Rs. 7,550.00
Sample Type: EDTA BLOOD
Fasting Not Required
Notes:T1170
Frequently Asked Questions (FAQ's):
What does the BCR-ABL IS P210 Quantitative test include?
Metropolis Healthcare measures the P210 BCR-ABL fusion transcript using RT-PCR and reports results on the International Scale for accurate monitoring.
Why is this test important?
This test at Metropolis Healthcare helps assess CML disease activity, treatment response, and minimal residual disease levels.
How does Metropolis Healthcare perform this test?
Metropolis Healthcare uses real-time PCR technology and international calibration standards to quantify BCR-ABL P210 transcripts precisely.
Who should take this test?
Patients diagnosed with chronic myeloid leukemia or undergoing targeted therapy should undergo periodic testing at Metropolis Healthcare.
What sample is required for this test?
EDTA blood is collected at Metropolis Healthcare to ensure RNA stability for accurate RT-PCR analysis.
How soon are results available?
Metropolis Healthcare provides timely reporting due to the clinical importance of monitoring CML progression and treatment response.
Can this test help monitor treatment effectiveness?
Yes, Metropolis Healthcare uses quantitative results to track molecular response and guide therapy adjustments.
Does Metropolis Healthcare assist in interpreting the report?
Metropolis Healthcare offers expert-reviewed molecular reports to help clinicians understand BCR-ABL levels and plan management accordingly